A New Target for Non-Small Cell Lung Cancer: Unlocking the Potential of Protein Phosphatase 2A
Lung cancer is a formidable disease, claiming the lives of more people than any other cancer in the United States. Over 80% of these cases are non-small cell lung cancers, characterized by larger and slower-growing tumor cells compared to their small cell counterparts. The genetic landscape of non-small cell lung cancer is complex, with many gene mutations playing a role. One such mutation, in the KRAS gene, is particularly significant as it drives cell growth and division, and is present in 30% of cases.
The challenge lies in the fact that patients with KRAS-mutated tumors often face shorter survival times and develop resistance to available therapies. However, a recent study published in The Journal of Clinical Investigation offers a glimmer of hope by identifying a new protein target and developing a drug to combat these aggressive cancers.
The researchers focused on Protein Phosphatase 2A (PP2A), a protein complex known to inhibit lung cancer development. Interestingly, the inability of PP2A to assemble is a common feature in lung, prostate, and liver cancers, prompting the scientists to explore whether stabilizing this complex could hinder tumor growth.
Through the use of cell lines derived from non-small cell lung cancers with KRAS mutations, the team discovered that the anti-cancer drugs adagrasib and trametinib disrupted the stability of PP2A. This finding provides a potential explanation for the emergence of resistance in patients treated with these drugs.
However, a breakthrough occurred when the researchers added a molecular glue called RPT04402, which stabilized the PP2A complex, leading to cancer cell death. These findings were further validated in mouse models, where the molecular glue caused tumor shrinkage.
The real game-changer was the combination of adagrasib or trametinib with RPT04402. This combination not only delayed resistance but also significantly increased treatment effectiveness, extending the survival of mice to over 150 days. Despite the promising results, the researchers emphasize that further studies are needed to determine the efficacy of this combination in all cases of non-small cell lung cancer.
The team is now gearing up for clinical trials in collaboration with Spring Works Therapeutics and Merck, with the hope of extending this research to other KRAS-mutant tumors and evaluating its potential in pancreatic and colon cancers. This study marks a significant step forward in the fight against non-small cell lung cancer, offering a new avenue for treatment and a glimmer of hope for patients facing this devastating disease.
